Immunogenicity of a Commercial Batch of the Japanese Encephalitis Vaccine IC51 up to Twenty-Four Months Post Filling. An Open-Label, Multicenter, Phase 3 Study.
Phase of Trial: Phase III
Latest Information Update: 06 May 2016
At a glance
- Drugs IC 51 (Primary)
- Indications Japanese encephalitis
- Focus Pharmacodynamics; Registrational
- Sponsors Valneva
- 24 Nov 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
- 24 Nov 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 12 Nov 2008 New trial record.